{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:40:39Z","timestamp":1793338839100,"version":"4.5.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Treatment of systemic lupus erythematosus (SLE) currently employs agents with relatively unselective immunosuppressive properties. However, two target-specific biological drugs have been approved: belimumab (anti-B-cell-activating factor\/BAFF) and anifrolumab (anti-interferon alpha receptor-1\/IFNAR1). Here, we performed a comparative risk-benefit assessment for both drugs based on the role of BAFF and IFNAR1 in host defense and the pathogenesis of SLE and by considering the available data on safety and efficacy. Due to differences in target expression sites, anti-IFNAR1, but not anti-BAFF, might elicit organ-specific effects, consistent with clinical efficacy data. The IFNAR1 is specifically involved in innate and adaptive antiviral immunity in most cells of the body. Consistent with this observation, the available safety data obtained from patients negatively selected for LN and neuropsychiatric SLE, primary immunodeficiencies, splenectomy and chronic HIV, HBV, HCV infections suggest an increased risk for some viral infections such as varicella zoster and perhaps influenza. In contrast, BAFF is mainly involved in adaptive immune responses in lymphoid tissues, thus anti-BAFF therapy modulates SLE activity and prevents SLE flares without interfering with local innate host defense mechanisms and should only marginally affect immune memory to previous pathogen exposures consistent with the available safety data from SLE patients without chronic HIV, HBV or HCV infections. When using belimumab and anifrolumab, careful patient stratification and specific precautions may minimize risks and maximize beneficial treatment effects for patients with SLE.<\/jats:p>","DOI":"10.3389\/fimmu.2022.980079","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T09:23:14Z","timestamp":1661937794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment"],"prefix":"10.3389","volume":"13","author":[{"given":"Kyriakos A.","family":"Kirou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dall`Era","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Aranow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: What have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01604-z","article-title":"Anifrolumab: First approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4245","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"Bmj"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in b cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat Microbiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409-101305","article-title":"An integrated view of humoral innate immunity: pentraxins as a paradigm","volume":"28","author":"Bottazzi","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R116.774562","article-title":"The molecular basis for differential type I interferon signaling","volume":"292","author":"Schreiber","year":"2017","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120156","article-title":"Innate immune sensing and signaling of cytosolic nucleic acids","volume":"32","author":"Wu","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/731023","article-title":"Interferon-regulatory factors determine macrophage phenotype polarization","volume":"2013","author":"G\u00fcnthner","year":"2013","journal-title":"Mediators Inflammation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type I interferons in autoimmune disease","volume":"14","author":"Crow","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.06.003","article-title":"New insights into b cells as antigen presenting cells","volume":"70","author":"Ghosh","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.24","article-title":"Altered b cell signalling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12640","article-title":"Generation of memory b cells and their reactivation","volume":"283","author":"Inoue","year":"2018","journal-title":"Immunol Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B cell responses: Cell interaction dynamics and decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"eabb1662","DOI":"10.1126\/sciimmunol.abb1662","article-title":"Human inborn errors of immunity: An expanding universe","volume":"5","author":"Notarangelo","year":"2020","journal-title":"Sci Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/cmr.00046-17","article-title":"The role of BAFF system molecules in host response to pathogens","volume":"30","author":"Sakai","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.05.016","article-title":"The roles of type I interferon in bacterial infection","volume":"19","author":"Boxx","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901120","article-title":"BAFF produced by neutrophils and dendritic cells is regulated differently and has distinct roles in antibody responses and protective immunity against West Nile virus","volume":"204","author":"Giordano","year":"2020","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.03497-13","article-title":"BAFF receptor deficiency limits gammaherpesvirus infection","volume":"88","author":"Frederico","year":"2014","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302960","article-title":"BAFF and BAFF receptor levels correlate with b cell subset activation and redistribution in controlled human malaria infection","volume":"192","author":"Scholzen","year":"2014","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the cytokine BAFF and autoimmunity risk","volume":"376","author":"Steri","year":"2017","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2005.00503.x","article-title":"The hemoglobinopathies and malaria","volume":"68","author":"Richer","year":"2005","journal-title":"Clin Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575103","article-title":"Evolutionarily selected overexpression of the cytokine BAFF enhances mucosal immune response against p","volume":"11","author":"Lodde","year":"2020","journal-title":"falciparum. Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"Randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits b lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-Two-Week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and south Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum. Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum. Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-Severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Investigators: Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum. Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312469259","article-title":"Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus","volume":"22","author":"Wallace","year":"2013","journal-title":"Lupus"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/art.40861","article-title":"Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221636","article-title":"Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum. Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06227-7","article-title":"Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management","volume":"81","author":"Mehta","year":"2022","journal-title":"Clin Rheumatol. 1-18"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/art.41598","article-title":"Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320959702","article-title":"Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials","volume":"29","author":"Koh","year":"2020","journal-title":"Lupus"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"2019 European League against Rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.014","article-title":"Long-lived plasma cells and their contribution to autoimmunity","volume":"1050","author":"Hoyer","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102361","article-title":"Monogenic lupus: Dissecting heterogeneity","volume":"18","author":"Omarjee","year":"2019","journal-title":"Autoimmun. Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev-med-050715-104506","article-title":"The type I interferonopathies","volume":"68","author":"Lee-Kirsch","year":"2017","journal-title":"Annu Rev Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838478","article-title":"Molecular mimicry in innate immunity? the viral RNA recognition receptor TLR7 accelerates murine lupus","volume":"38","author":"Anders","year":"2008","journal-title":"Eur J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature09102","article-title":"TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus","volume":"465","author":"Guiducci","year":"2010","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050630","article-title":"RNA-Associated autoantigens activate b cells by combined b cell antigen receptor\/Toll-like receptor 7 engagement","volume":"202","author":"Lau","year":"2005","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2006101162","article-title":"Inhibition of toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus","volume":"18","author":"Pawar","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/art.23407","article-title":"Requirement of toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis","volume":"58","author":"Savarese","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B60","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.clim.2016.07.015","article-title":"Toll-like receptor activation in the pathogenesis of lupus nephritis","volume":"185","author":"Lorenz","year":"2017","journal-title":"Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22971","article-title":"Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283025ed4","article-title":"The role of innate immunity in autoimmune tissue injury","volume":"20","author":"Allam","year":"2008","journal-title":"Curr Opin Rheumatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","article-title":"Toll-like receptor signalling in b cells during systemic lupus erythematosus","volume":"17","author":"Fillatreau","year":"2021","journal-title":"Nat Rev Rheumatol."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun. Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000596","article-title":"The role of cutaneous type I IFNs in autoimmune and autoinflammatory diseases","volume":"205","author":"Turnier","year":"2020","journal-title":"J Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12974-020-02003-z","article-title":"Microglial responses to peripheral type 1 interferon","volume":"17","author":"Aw","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/art.22578","article-title":"Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus","volume":"56","author":"Nzeusseu Toukap","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13379","article-title":"Neutralizing interferon-\u03b1 blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus","volume":"164","author":"Ding","year":"2021","journal-title":"Immunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210391","article-title":"High systemic type I interferon activity is associated with active class III\/IV lupus nephritis","volume":"49","author":"Iwamoto","year":"2022","journal-title":"J Rheumatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cyto.2016.02.006","article-title":"Cytokines and persistent viral infections","volume":"82","author":"Beltra","year":"2016","journal-title":"Cytokine"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/fmkp4b","article-title":"Association of influenza infection with hospitalisation-related systemic lupus erythematosus flares: a time series analysis","volume":"39","author":"Joo","year":"2021","journal-title":"Clin Exp Rheumatol."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04825-3","article-title":"Plasmacytoid dendritic cells and type I interferons in flares of systemic lupus erythematosus triggered by COVID-19","volume":"41","author":"Nasser","year":"2021","journal-title":"Rheumatol. Int"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/art.39682","article-title":"Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: Pooled analyses from the phase III belimumab trials","volume":"68","author":"van Vollenhoven","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a b lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum. Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum. Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214043","article-title":"Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis","volume":"78","author":"Urowitz","year":"2019","journal-title":"Ann Rheum. Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: A continuation of a seventy-Six-Week phase III parent study in the united states","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez279","article-title":"Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a phase III study extension","volume":"59","author":"van Vollenhoven","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum. Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0040","article-title":"Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus","volume":"11","author":"Bruce","year":"2022","journal-title":"J Comp Eff Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0346-x","article-title":"Dysregulation of type I interferon responses in COVID-19","volume":"20","author":"Acharya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2020.0076","article-title":"Protective potentials of type III interferons in COVID-19 patients: Lessons from differential properties of type I- and III interferons","volume":"34","author":"Jafarzadeh","year":"2021","journal-title":"Viral Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Casanova: Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202106_26060","article-title":"Antiviral drugs proposed for COVID-19: action mechanism and pharmacological data","volume":"25","author":"Rommasi","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24931","article-title":"Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19","volume":"327","year":"2022","journal-title":"Jama"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.980079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T09:23:17Z","timestamp":1661937797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.980079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":89,"alternative-id":["10.3389\/fimmu.2022.980079"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.980079","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"980079"}}